One-year pilot study on the effects of nitisinone on melanin in patients with OCA-1B.
Abstract | BACKGROUND: METHODS: In this open-label pilot study, 5 adult patients with OCA-1B established baseline measurements of iris, skin, and hair pigmentation and were treated over 12 months with 2 mg/d oral nitisinone. Changes in pigmentation and visual function were evaluated at 3-month intervals. RESULTS: The mean change in iris transillumination, a marker of melanin, from baseline was 1.0 ± 1.54 points, representing no change. The method of iris transillumination grading showed a high intergrader reliability (intraclass correlation coefficient ≥ 0.88 at each visit). The number of letters read (visual acuity) improved significantly at month 12 for both eyes (right eye, OD, mean 4.2 [95% CI, 0.3, 8.1], P = 0.04) and left eye (OS, 5 [1.0, 9.1], P = 0.003). Skin pigmentation on the inner bicep increased (M index increase = 1.72 [0.03, 3.41], P = 0.047). Finally, hair pigmentation increased by both reflectometry (M index [17.3 {4.4, 30.2}, P = 0.01]) and biochemically. CONCLUSION:
Nitisinone did not result in an increase in iris melanin content but may increase hair and skin pigmentation in patients with OCA-1B. The iris transillumination grading scale used in this study proved robust, with potential for use in future clinical trials. TRIAL REGISTRATION: CLINICALTRIALS: gov NCT01838655. FUNDING: Intramural program of the National Eye Institute.
|
Authors | David R Adams, Supriya Menezes, Ramon Jauregui, Zaheer M Valivullah, Bradley Power, Maria Abraham, Brett G Jeffrey, Angel Garced, Ramakrishna P Alur, Denise Cunningham, Edythe Wiggs, Melissa A Merideth, Pei-Wen Chiang, Shanna Bernstein, Shosuke Ito, Kazumasa Wakamatsu, Rhona M Jack, Wendy J Introne, William A Gahl, Brian P Brooks |
Journal | JCI insight
(JCI Insight)
Vol. 4
Issue 2
(Jan 24 2019)
ISSN: 2379-3708 [Electronic] United States |
PMID | 30674731
(Publication Type: Journal Article)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|